Clin Asst Prof Lai Geet Yi Gillianne

Dr Gillianne Lai is a Consultant Medical Oncologist at the National Cancer Centre Singapore, sub-specializing in thoracic, head and neck and genitourinary cancers. She received her undergraduate training from the Yong Loo Lin School of Medicine, National University of Singapore and is a member of the Royal College of Physicians of the United Kingdom.

She completed her Medical Oncology specialty training at the National Cancer Centre Singapore. She has a strong interest in thoracic oncology and is actively involved in research. She currently leads that Lung Cancer Consortium Singapore (LCCS), and is the Principal Investigator of the National Lung Cancer Research (NLCR) study which aims to improve lung cancer care through 4 main themes: (1) understanding the origins of lung cancer, (2) improving risk stratification of disease, (iii) identifying better response biomarkers, and (4) understanding resistance mechanisms. She is also the chairperson of the Singhealth Lung Centre Pulmonary Nodule Workgroup and has a keen interest in lung cancer screening.

• MRCP (UK) and MMed (Internal Medicine), 2015
• MBBS, National University of Singapore, 2012

• Consultant, Division of Medical Oncology, National Cancer Centre Singapore
• International Association for the Study of Lung Cancer (IASLC), Member
• European Society for Medical Oncology (ESMO), Member
• Singapore Society of Oncology (SSO), Member
• Physician Faculty Member, Singhealth Medical Oncology Residency Programme
  

• Singhealth Publish! Award 2020
• Young Investigator's Travel Award, IASLC 18^th World Conference of Lung Cancer 2017
• Outstanding Resident Award (Singhealth Residency) 2017
• Best Medical Officer Award 2014

• ​Thoracic Oncology

• Chua KP, Teng YHF, Tan AC, Takano A, Alvarez JJS, Nahar, R, Rohatgi N, Lai GGY, Aung ZW, Yeong JPS, Lim KH, Naeini MM, Kassam I, Jain A, Tan WL, Gogna A, Too CW, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Anantham D, Phua GC, Tan BS, Lee YY, Wang L, Teo ASM, Khng AJ, Lim MJ, Suteja L, Toh CK, Lim WT, Iyer NG, Tam WL, Tan EH, Zhai W, Hillmer AM, Skanderup AJ, Tan DSW. Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transit and Therapeutic Opportunities. Clinc Cancer Res 2021 Nov 1;27(21):5939-5950.
• Tan AC, Seet AOL, Lai GGY, Lim TH, Lim AST, Tan GS, Takano A, Tai DWM, Tan TJY, Ng MCH, Tan WL, Ang MK, Kanevaran R, Ng QS, Jain A, Rajasekaran T, Lim WT, Tan EH, Lim KH, Tan DSW. Molecular characterization and clinical outcomes of RET-Rearranged NSCLC. Journal of Thoracic Oncology 2020;15(12):1928-1934.
• Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 2020;139:207-215.
• Chua T, Chan J, Lai G, Yong T, Kanesvaran R, Anatharaman V. Management of oncology-related emergencies at the emergency department (MORE-ED) – a long-term undertaking. Journal of Emergency Medicine 2019; 57(3):423.
• Tan AC, Teh YL, Lai GGY, Tan DSW. Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). Expert Rev Anticancer Ther 2019;19(6):431-435.
• Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, Aung ZW, Takano A, Lee YY, Lau DPX, Tan GS, Tan SH, Tan WL, Ang MK, Toh CK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Yuan J, Lim TKH, Lim AST, Hillmer AM, Lim WT, Iyer NG, Tam WL, Zhai W, Tan EH, Tan DSW. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidgermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol 2019;37(11):876-884.
• A Drilon, ZI Hu, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature Reviews Clinical Oncology 2017;15(3):151-167.
• Lai G, Koo YX, Tan TT, Lim ST. Use of Rituximab in Combination with High-Dose Methotrexate in the Treatment of Primary Central Nervous System Lymphoma in a Mycophenolate Mofetil Treated Patient with Lupus Nephritis. Acta Oncological 2011; 50(1):144-145.
• Lai G, Penson RT. Bevacizumab and ovarian cancer. Drugs of Today 2011; 47(9): 669-681.
• Lai G, Lim ST, Tao M, Chan A, Li H, Quek R. Late-Onset Neutropenia Following RCHOP Chemotherapy in Diffuse Large B-Cell Lymphoma. American Journal of Hematology 2009; 84(7): 414-417.